{"product_id":"shionogi-ansoff-matrix","title":"Shionogi \u0026 Co Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Shionogi \u0026amp; Co Amsoff Matrix Analysis gives a clear view of the company’s growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the actual analysis, so you can see the structure and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFetroja share gains in 3 hospital regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFetroja kept winning hospital share in Japan, the United States, and Europe in fiscal 2025, showing classic market penetration for an on-market drug. Shionogi reported cefiderocol sales of ¥34.8 billion in FY2025, up 17% year on year, helped by formulary access, stewardship reviews, and real-world data in multidrug-resistant Gram-negative infections. More hospital use here means deeper unit growth, not a new product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXocova demand capture during 2025 to 2026 respiratory season\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. is pushing ensitrelvir to defend Japan outpatient COVID-19 share in the 2025-2026 respiratory season. Penetration is strongest in seasonal spikes, early use within 5 days of symptoms, and repeat prescribing by physicians who already know a 1-product antiviral option. Demand capture hinges on pharmacy stock and steady clinical awareness, not a new launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNaldemedine depth in 2 major branded markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. is using naldemedine to deepen use in opioid-induced constipation across the United States and Japan, where the drug already has an established branded base. The main lever is not expansion into new geographies, but better conversion and repeat prescribing among pain, gastroenterology, and primary-care doctors, which is classic market penetration. That matters because growth comes from taking more share inside a defined specialty market, not from a new launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led commercialization across 3 regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. uses partner-led commercialization across 3 regions to expand selected assets without building full sales forces. That fits hospital antibiotics and antivirals, where local access, tendering, and reimbursement often decide uptake. The model lowers expansion cost, speeds market entry, and lets Shionogi \u0026amp; Co., Ltd. keep capital on core therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics attachment in 2 care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can deepen market penetration by tying diagnostics to treatment in two care pathways: respiratory infections and hospital-acquired infections. Faster test results can move clinicians to start therapy sooner, which lifts pull-through for the same antimicrobial brands instead of adding new ones. In 2025, that matters because faster testing in these workflows shortens decision time and can increase treatment starts per screened patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShionogi’s FY2025 Growth Came From Deeper Share, Not New Launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. drove market penetration in FY2025 by squeezing more share from on-market brands, not by adding new launches. Fetroja sales reached ¥34.8 billion, up 17%, while naldemedine and ensitrelvir kept expanding use in defined hospital and outpatient niches. The play is tighter access, faster prescribing, and repeat use inside existing markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetroja\u003c\/td\u003e\n\u003ctd\u003e¥34.8 billion, +17%\u003c\/td\u003e\n\u003ctd\u003eHospital share gains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnsitrelvir\u003c\/td\u003e\n\u003ctd\u003eJapan seasonal demand\u003c\/td\u003e\n\u003ctd\u003eRepeat prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNaldemedine\u003c\/td\u003e\n\u003ctd\u003eBranded base expanded\u003c\/td\u003e\n\u003ctd\u003eConversion and repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Amsoff Matrix view of Shionogi \u0026amp; Co’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Shionogi \u0026amp; Co quickly pinpoint growth options and reduce strategic guesswork with a clear, easy-to-use Ansoff Matrix.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnsitrelvir expansion beyond Japan into new countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnsitrelvir, approved in Japan in 2022, has also been rolled out in Singapore and Taiwan, so Shionogi \u0026amp; Co., Ltd. is using one oral antiviral to enter new national markets. That is classic market development: the product is already proven, but the customer base and regulatory footprint keep expanding. With COVID-19 still causing seasonal spikes, expanding ensitrelvir beyond Japan gives Shionogi \u0026amp; Co., Ltd. a faster path to growth than waiting for a new asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFetroja registration in additional hospital markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can push cefiderocol into more hospital systems across Asia and Latin America, where WHO estimates antimicrobial resistance caused 1.27 million deaths in 2019. Its track record in hard-to-treat Gram-negative infections helps new-country registration and partner-led launches. Market development will still hinge on local price cuts, stewardship approval, and hospital buying cycles that can take months. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNaldemedine licensing into 2 to 3 new geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2025, Shionogi \u0026amp; Co., Ltd. can widen naldemedine into 2-3 new geographies through local licensing and distribution deals, because the molecule is already proven. Opioid-induced constipation affects about 40%-60% of chronic opioid users, so the best targets are markets with heavy opioid use and weak constipation care. This is market development: same drug, bigger addressable geography.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital diagnostics into new public-health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can expand Shionogi \u0026amp; Co., Ltd. diagnostics by selling reagents into public-health labs, hospital networks, and infection-control programs that still rely on older testing workflows. The pitch is strongest when one result can change treatment and isolation fast, cutting wasted antibiotics and beds. In hospital settings, that speed matters because even a 1-day delay can spread infection and raise care cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsia-Pacific expansion through local partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can use regional partners to enter Asia-Pacific faster, because local firms already hold licenses, distribution, and hospital access.\u003c\/p\u003e\n\u003cp\u003eThat matters for specialty drugs, where one or two tertiary hospitals can drive early demand and keep launch costs lower than building a full direct sales force.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, this model helps protect operating margin by limiting upfront SG\u0026amp;A while scaling reach country by country.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShionogi’s FY2025 growth play: proven drugs, new markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Shionogi \u0026amp; Co., Ltd. kept market development focused on taking proven assets into new countries, led by ensitrelvir, cefiderocol, and naldemedine. That works because launch risk is lower than R\u0026amp;D risk, and partner-led rollout can scale faster than a full local sales build. The playbook fits Asia-Pacific and other high-need markets where access gaps are still wide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 use\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnsitrelvir\u003c\/td\u003e\n\u003ctd\u003eNew-country launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCefiderocol\u003c\/td\u003e\n\u003ctd\u003eHospital expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNaldemedine\u003c\/td\u003e\n\u003ctd\u003eLicensing-led entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eShionogi \u0026amp; Co Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Shionogi \u0026amp; Co Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just the full report. The preview below comes directly from the complete document, so what you see here is exactly what you’ll get. Unlock the full, detailed version after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnsitrelvir lifecycle extensions into 2025 programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. is still developing ensitrelvir beyond its first COVID-19 use case, with 2025 work aimed at broader clinical utility, easier dosing, and label expansion. That fits the product-development play in the Ansoff Matrix: one approved product can keep growing through new data and new patient groups. The key value is that a single launch can be extended into new settings without starting from zero.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-generation anti-infectives for resistant pathogens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. is using product development to build the next asset after cefiderocol, aimed at hospital-treated resistant bacterial infections. This matters because the antibiotic market pays for clear clinical differentiation, not just volume, and Shionogi \u0026amp; Co., Ltd. kept R\u0026amp;D spending above ¥100 billion in FY2025 to fund that pipeline. With cefiderocol as proof of reach in this niche, the next-generation anti-infectives strategy is a direct bet on higher-value, harder-to-treat pathogens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain and CNS pipeline readouts in the 2025 to 2026 window\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. is using pain and CNS as a second innovation engine, with readouts due in the 2025 to 2026 window. That matters because one successful launch can reuse its clinical, regulatory, and commercial setup, so each new asset costs less to move than a fresh franchise. The payoff is portfolio balance: growth is not tied only to one infectious-disease cycle, and even one approved pain or CNS product can open a large, long-duration market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew formulations for hospital and outpatient use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can extend an asset’s life by moving it from inpatient use to simpler outpatient care through new dose forms, packaging, or routes like oral or self-use delivery. This fits product development in the Ansoff Matrix because it lifts value from an existing molecule without the cost and risk of a new drug. For FY2025, that kind of lifecycle work supports faster adoption, lower care burden, and broader use across hospital and clinic settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic reagent upgrades for faster workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can upgrade diagnostic reagents to cut run time, raise accuracy, and make testing simpler in routine labs. In infectious disease, faster diagnosis can link patients to treatment sooner, which supports Shionogi \u0026amp; Co., Ltd.'s drug sales and follow-on use. This fits product development: diagnostics and therapeutics work together, and Shionogi \u0026amp; Co., Ltd. reported FY2025 net sales of ¥426.7 billion, giving it scale to fund such upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShionogi \u0026amp; Co., Ltd. extends one molecule into more markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. uses product development to extend approved assets like ensitrelvir into new uses and patient groups, which lowers launch risk and lifts value from one molecule. FY2025 R\u0026amp;D stayed above ¥100 billion, supporting pipeline work in resistant infections, pain, and CNS. The payoff is a wider revenue base without starting new franchises from zero.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e¥426.7 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;¥100 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics and medical devices as 2 adjacent businesses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. already sits beyond pure pharmaceuticals because it sells diagnostic reagents and medical devices alongside prescription drugs. That is adjacent diversification: the products stay in healthcare, but customers, buying cycles, and margins differ from drug sales.\u003c\/p\u003e\n\u003cp\u003eIt also reduces reliance on prescriptions alone, which matters as FY2025 revenue mix stayed tied to a broader healthcare franchise rather than one product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTest-and-treat solutions for infection workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Shionogi \u0026amp; Co., Ltd. reported net sales of about ¥438 billion, giving it room to build beyond pills into service-led care. Test-and-treat workflows bundle diagnostics, diagnosis, and therapy selection, so hospitals can move faster and cut handoffs. That fits public-health buyers that pay for speed, outcomes, and simple operations. It also shifts Shionogi \u0026amp; Co., Ltd. toward a stickier, system-based model than drug sales alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData-enabled infection management partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can diversify into data-led infection management by selling decision-support, surveillance, and utilization tools, not just drugs. In FY2025, that matters because hospitals now demand proof of lower costs, faster isolation, and better antibiotic use. The upside is recurring service revenue tied to measurable clinical outcomes, which can be stickier than unit sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelective entry into new therapeutic platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. uses selective in-licensing and alliances to move into new therapeutic platforms, so the customer base and product mix can shift well beyond infectious disease and pain\/CNS. That is diversification, but it stays disciplined: the firm can reuse its development and regulatory skills instead of chasing unrelated bets. In FY2025, this fit matters because higher R\u0026amp;D efficiency is key for each new platform entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth security and preparedness assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. can diversify into health security and preparedness assets by expanding antivirals, rapid diagnostics, and hospital-readiness tools. That theme is credible because the company already has deep anti-infective science, and outbreak demand can spike fast: COVID-19 showed global cases topped 770 million by 2023. These assets add a second demand pool beyond routine care and fit a shock-response model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShionogi broadens growth beyond prescription drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShionogi \u0026amp; Co., Ltd. uses diversification to widen beyond prescription drugs into diagnostics, devices, and service-led infection management. In FY2025, net sales were about ¥438 billion, so this broader mix helps reduce reliance on any one product line and supports recurring, system-based revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 fact\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales: ¥438 billion\u003c\/td\u003e\n\u003ctd\u003eShows scale for new bets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics and devices\u003c\/td\u003e\n\u003ctd\u003eAdjacent revenue beyond drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest-and-treat workflows\u003c\/td\u003e\n\u003ctd\u003eMore sticky hospital sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53651726205270,"sku":"shionogi-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/shionogi-ansoff-analysis.webp?v=1778898016","url":"https:\/\/balancedscorecardexamples.com\/products\/shionogi-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}